01634nam a22002537a 4500001001300000003000400013005001700017008004100034020001500075040000800090245011200098260003700210300001900247336002100266337002500287338002200312501011200334520077300446700002401219700001801243700002401261700002101285856007401306D0001B001256DOH20210123114310.0210123b           ||||| |||| 00| 0 eng d  a1586033344  erda00aDrugs and money  :bprices, affordability and cost containment  /cEdited by M.N.G. Dukes [and four others]  aAmsterdam :bIOS Press,c© 2003  aVI, 152 pages.  2rdacontentatext  2rdamediaaunmediated  2rdacarieravolume  aPublished on behalf of the World Health Organization Regional Office for Europe by IOS Press -- Title page.2 aContent:  1. Scope of the problem. -- 2. Data needed for developing and monitoring policies. -- 3. Policy options for cost containment of  pharmaceuticals -- 4. Methods for monitoring and evaluating processes and outcomes. -- 5. Making use of economic evaluation. -- 6. Measures relating to use of drug subsidy lists and to regulation. -- 7. Experiences with budgets. -- 8. Experiences with reference pricing. -- 9. Experiences with patient charges. -- 10. Switching to non-prescription status. -- 11. Experiences with generics. -- 12. Experiences with pharmacy benefit management programmes in the USA. -- 13. Experiences with professional education. -- 14. Providing affordable medicines in transitional countries. --
15. Access to medicines in low-income countries.1 aDukes, M.N. Graham 1 aGraham, M.N. 1 aJoncheere, Kees de 1 aRietveld, Ad H.   uhttps://www.euro.who.int/__data/assets/pdf_file/0011/96446/e79122.pdf